Transforming India’s Pharmaceutical Landscape: Biopharma SHAKTI

India’s Union Budget 2026-27 unveiled a groundbreaking initiative known as Biopharma SHAKTI, a national mission with a budget of ₹10,000 crore aimed at propelling India into a global hub for high-value biologics and biosimilars. This strategic move signifies a shift from India’s traditional focus on generic drugs towards innovation-driven biopharmaceuticals.

Global Pharmaceutical Industry Evolution

The global pharmaceutical sector has undergone significant structural changes in recent years, moving from small-molecule drugs to complex biologics and precision therapies. Biologics now account for a substantial portion of global pharmaceutical revenue, with the United States, Europe, and China leading the way in innovation and production.

India’s Pharmaceutical Strengths

India has long been recognized as the “Pharmacy of the World,” excelling in the production of generic medicines. However, the country’s share in the high-value biopharmaceutical market remains limited. Biopharma SHAKTI aims to address this gap by enhancing domestic manufacturing capabilities and research infrastructure.

Strategic Objectives of Biopharma SHAKTI

One of the key goals of Biopharma SHAKTI is to capture 5% of the global biopharmaceutical market, which would significantly boost India’s export revenues. By focusing on innovation, infrastructure expansion, clinical trials, regulatory strengthening, and governance, the initiative aims to elevate India’s pharmaceutical sector to new heights of global competitiveness.

Impact and Benefits

Biopharma SHAKTI has the potential to strengthen India’s export profile, diversify markets, and enhance the country’s brand image as an innovation-driven biotechnology hub. By aligning with India’s developmental vision of Viksit Bharat @ 2047, the initiative can boost GDP growth, create employment opportunities, and improve access to life-saving therapies for millions of Indians.

From Volume to Value: The Future of Indian Pharma

Biopharma SHAKTI represents a pivotal moment in India’s healthcare and industrial policy, paving the way for the country to lead in innovation-led biologics and advanced therapies. By combining existing strengths with technological advancements, India’s pharmaceutical sector can transition to a global leadership model based on technology and innovation.

As India progresses towards Viksit Bharat @ 2047, Biopharma SHAKTI emerges as a transformative initiative that positions the country as a global powerhouse in biopharmaceutical innovation and manufacturing excellence.

For more information, please contact the author at shiveshemail@gmail.com